Nelson Vergel (PowerUSA.org) moderates a webcast with two leading HIV Cure research activists: Richard Jeffreys and Robert Reinhard. They update us on progress made after a cure was possible for Timothy Brown, the only person cured of HIV in 2007. ABOUT THE SPEAKERS: Richard Jefferys began working in the HIV/AIDS field in 1993 at the …
HIV Cure Update 2017: Interview with Leading Research Advocates Read More »
(Los Angeles, CA) — The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual …
Calimmune Initiates HIV Stem Cell Study at Two California Research Sites Read More »
I highly encourage everyone to join our important attempt to accelerate the cure of HIV. Research Match also helps connect patients with other diseases with private investigators. Please forward to your friends and families. Anyone can participate. Thank you in advance for supporting this platform! Contact: Kathy Edson (615) 343-2571/ kathleen.edson@vanderbilt.edu ResearchMatch Connects HIV Study Volunteers with Researchers Nashville, TN – June 1, 2013 — ResearchMatch (RM), the country’s first nationwide, non-profit research volunteer recruitment platform for all …
ResearchMatch Connects HIV Study Volunteers with Researchers Read More »
SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-T Unprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials Richmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new …
One of the greatest advances in modern medicine has been the development of HAART for the treatment of HIV. HAART decreases HIV-associated morbidity and mortality for patients with regular access to these medications, but it does not appear to completely restore their health for reasons that currently are unclear. As a result, there has been …
IMMUNE BASED THERAPIES Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients The purpose of this research study is to find out whether “zinc finger” modified CD4+ T-cells are safe to give to humans and find how “zinc finger” modified T-cell affects HIV. …
